Thrombophilia, antikoaguláns terápia és terhesség.

Translated title of the contribution: Thrombophilia, anticoagulant therapy and pregnancy

Z. Boda, P. László, G. Pfliegler, I. Tornai, L. Rejtö, A. Schlammadinger

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Thromboembolic complications during pregnancy are the most common causes of maternal death. Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial thrombophilia. Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy. UFH (Heparin-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories. Artificial abortions were not included in this paper. The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3%), with UFH (Heparin-Ca): 8/11 (72.7%), without prophylaxis: 4/23 (17.4%). In the patient group treated with Fraxiparine there were no foetopathy, thrombocytopenia or bleeding complication. LMWH is recommended for pregnant women with familial thrombophilia. According to literature data and our own experiences the doses of LMWH in patients with familial thrombophilia, and -antiphospholipid syndrome, and -artificial heart value are suggested.

Original languageHungarian
Pages (from-to)3113-3116
Number of pages4
JournalOrvosi Hetilap
Volume139
Issue number52
Publication statusPublished - Dec 27 1998

Fingerprint

Thrombophilia
Nadroparin
Anticoagulants
Pregnancy
Low Molecular Weight Heparin
Pregnant Women
Artificial Heart
Maternal Death
Pregnancy Complications
Therapeutics
Thrombocytopenia
Cause of Death
Hemorrhage
calcium heparin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Boda, Z., László, P., Pfliegler, G., Tornai, I., Rejtö, L., & Schlammadinger, A. (1998). Thrombophilia, antikoaguláns terápia és terhesség. Orvosi Hetilap, 139(52), 3113-3116.

Thrombophilia, antikoaguláns terápia és terhesség. / Boda, Z.; László, P.; Pfliegler, G.; Tornai, I.; Rejtö, L.; Schlammadinger, A.

In: Orvosi Hetilap, Vol. 139, No. 52, 27.12.1998, p. 3113-3116.

Research output: Contribution to journalArticle

Boda, Z, László, P, Pfliegler, G, Tornai, I, Rejtö, L & Schlammadinger, A 1998, 'Thrombophilia, antikoaguláns terápia és terhesség.', Orvosi Hetilap, vol. 139, no. 52, pp. 3113-3116.
Boda Z, László P, Pfliegler G, Tornai I, Rejtö L, Schlammadinger A. Thrombophilia, antikoaguláns terápia és terhesség. Orvosi Hetilap. 1998 Dec 27;139(52):3113-3116.
Boda, Z. ; László, P. ; Pfliegler, G. ; Tornai, I. ; Rejtö, L. ; Schlammadinger, A. / Thrombophilia, antikoaguláns terápia és terhesség. In: Orvosi Hetilap. 1998 ; Vol. 139, No. 52. pp. 3113-3116.
@article{e8c5abbc82a048719e3a7baabe1af9ea,
title = "Thrombophilia, antikoagul{\'a}ns ter{\'a}pia {\'e}s terhess{\'e}g.",
abstract = "Thromboembolic complications during pregnancy are the most common causes of maternal death. Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial thrombophilia. Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy. UFH (Heparin-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories. Artificial abortions were not included in this paper. The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3{\%}), with UFH (Heparin-Ca): 8/11 (72.7{\%}), without prophylaxis: 4/23 (17.4{\%}). In the patient group treated with Fraxiparine there were no foetopathy, thrombocytopenia or bleeding complication. LMWH is recommended for pregnant women with familial thrombophilia. According to literature data and our own experiences the doses of LMWH in patients with familial thrombophilia, and -antiphospholipid syndrome, and -artificial heart value are suggested.",
author = "Z. Boda and P. L{\'a}szl{\'o} and G. Pfliegler and I. Tornai and L. Rejt{\"o} and A. Schlammadinger",
year = "1998",
month = "12",
day = "27",
language = "Hungarian",
volume = "139",
pages = "3113--3116",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "52",

}

TY - JOUR

T1 - Thrombophilia, antikoaguláns terápia és terhesség.

AU - Boda, Z.

AU - László, P.

AU - Pfliegler, G.

AU - Tornai, I.

AU - Rejtö, L.

AU - Schlammadinger, A.

PY - 1998/12/27

Y1 - 1998/12/27

N2 - Thromboembolic complications during pregnancy are the most common causes of maternal death. Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial thrombophilia. Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy. UFH (Heparin-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories. Artificial abortions were not included in this paper. The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3%), with UFH (Heparin-Ca): 8/11 (72.7%), without prophylaxis: 4/23 (17.4%). In the patient group treated with Fraxiparine there were no foetopathy, thrombocytopenia or bleeding complication. LMWH is recommended for pregnant women with familial thrombophilia. According to literature data and our own experiences the doses of LMWH in patients with familial thrombophilia, and -antiphospholipid syndrome, and -artificial heart value are suggested.

AB - Thromboembolic complications during pregnancy are the most common causes of maternal death. Here we report on thromboembolic prophylaxis of 60 pregnancies of 32 pregnant women with familial thrombophilia. Long-term Fraxiparine (Sanofi-Chinoin) as thromboprophylaxis was applied in 26 cases throughout pregnancy. UFH (Heparin-Ca inj.) was used in 11 cases, and there were 23 pregnancies without thromboembolic prophylaxis in our patient's case histories. Artificial abortions were not included in this paper. The ratio of successful pregnancies were: with Fraxiparine: 24/26 (92.3%), with UFH (Heparin-Ca): 8/11 (72.7%), without prophylaxis: 4/23 (17.4%). In the patient group treated with Fraxiparine there were no foetopathy, thrombocytopenia or bleeding complication. LMWH is recommended for pregnant women with familial thrombophilia. According to literature data and our own experiences the doses of LMWH in patients with familial thrombophilia, and -antiphospholipid syndrome, and -artificial heart value are suggested.

UR - http://www.scopus.com/inward/record.url?scp=18344401375&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18344401375&partnerID=8YFLogxK

M3 - Article

C2 - 9914731

AN - SCOPUS:18344401375

VL - 139

SP - 3113

EP - 3116

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 52

ER -